ATE434404T1 - Alternativ gesplicter zirkulierender gewebefaktor - Google Patents

Alternativ gesplicter zirkulierender gewebefaktor

Info

Publication number
ATE434404T1
ATE434404T1 AT02797784T AT02797784T ATE434404T1 AT E434404 T1 ATE434404 T1 AT E434404T1 AT 02797784 T AT02797784 T AT 02797784T AT 02797784 T AT02797784 T AT 02797784T AT E434404 T1 ATE434404 T1 AT E434404T1
Authority
AT
Austria
Prior art keywords
alt
htf
tissue factor
elevated
human tissue
Prior art date
Application number
AT02797784T
Other languages
English (en)
Inventor
Yale Nemerson
Vladimir Bogdanov
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Application granted granted Critical
Publication of ATE434404T1 publication Critical patent/ATE434404T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02797784T 2001-08-30 2002-08-29 Alternativ gesplicter zirkulierender gewebefaktor ATE434404T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31624401P 2001-08-30 2001-08-30
PCT/US2002/027533 WO2003020111A2 (en) 2001-08-30 2002-08-29 Alternatively spliced circulating tissue factor

Publications (1)

Publication Number Publication Date
ATE434404T1 true ATE434404T1 (de) 2009-07-15

Family

ID=23228197

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797784T ATE434404T1 (de) 2001-08-30 2002-08-29 Alternativ gesplicter zirkulierender gewebefaktor

Country Status (6)

Country Link
US (1) US7045350B2 (de)
EP (1) EP1429650B1 (de)
AT (1) ATE434404T1 (de)
AU (1) AU2002361471A1 (de)
DE (1) DE60232733D1 (de)
WO (1) WO2003020111A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2475447A1 (en) * 2002-02-07 2003-08-14 Hans Prydz Short interfering rna molecules directed towards a tissue factor coding nucleic acid
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
WO2008054822A2 (en) * 2006-11-03 2008-05-08 Angiogen Llc Compositions comprising alternatively spliced tissue factor (as tf) and methods for use
US20090042869A1 (en) * 2007-06-20 2009-02-12 University Of Utah Research Foundation SIGNAL-DEPENDENT SPLICING OF TISSUE FACTOR PRE-mRNA IN PLATELET CELLS
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
WO2011144953A1 (en) * 2010-05-18 2011-11-24 Diagon Kft. Procedure for producing recombinant human tissue factor
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
US9555109B2 (en) 2012-01-20 2017-01-31 University Of Cincinnati Method of inhibiting cell proliferation induced by alternatively spliced tissue factor by administering a monoclonal antibody
US10204181B1 (en) * 2015-07-10 2019-02-12 Omnisent LLC Systems and methods for modeling quantum structure and behavior
US10637583B2 (en) * 2015-07-10 2020-04-28 Omnisent, LLC Systems and methods for modeling quantum entanglement and performing quantum communication
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
JP7460608B2 (ja) 2018-05-07 2024-04-02 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4244946A (en) * 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) * 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) * 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4629784A (en) * 1983-08-16 1986-12-16 The University Of Georgia Research Foundation, Inc. Synthesis of cyclopropane amino acids
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) * 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4789734A (en) * 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4925673A (en) * 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
AU3651689A (en) 1988-06-17 1989-12-21 Mount Sinai School Of Medicine Of The City University Of New York, The Cloning and expression of human tissue factor
CA1340977C (en) 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5211947A (en) * 1988-12-16 1993-05-18 Schering Corporation Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor
JPH03290184A (ja) 1990-04-06 1991-12-19 Chugai Pharmaceut Co Ltd スカベンジャーレセプター産生動物細胞
JP3594318B2 (ja) 1990-08-27 2004-11-24 中外製薬株式会社 抗ヒトスカベンジャーレセプター抗体
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
AU659482B2 (en) 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
AU3814393A (en) 1992-03-23 1993-10-21 University Of North Carolina At Chapel Hill, The Small animal model for studying cholesterol metabolism
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US6429289B1 (en) 1994-06-23 2002-08-06 Massachusetts Institute Of Technology Class BI and CI scavenger receptors
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake

Also Published As

Publication number Publication date
AU2002361471A1 (en) 2003-03-18
US7045350B2 (en) 2006-05-16
DE60232733D1 (de) 2009-08-06
US20030049784A1 (en) 2003-03-13
EP1429650A4 (de) 2005-11-23
WO2003020111A3 (en) 2004-01-29
EP1429650A2 (de) 2004-06-23
EP1429650B1 (de) 2009-06-24
WO2003020111A2 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
DE60232733D1 (de) Alternativ gesplicter zirkulierender gewebefaktor
DE69736197D1 (de) Antikoagulierende humanisierte Antikörper gegen Faktor IX, zur Verwendung in der Behandlung von Thrombose
DK1140969T3 (da) Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
PT988301E (pt) Acetais ciclicos de imidazolilo
CY1111626T1 (el) ΠΑΡΑΛΛΑΓΕΣ ΠΟΛΥΠΕΠΤΙΔΙΩΝ ΠΑΡΑΓΟΝΤΑ VII ´H VIIa
EP1049767A4 (de) Transgenes kaninchen, das ein funktionelles menschliches lipoprotein exprimiert
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE359807T1 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
WO2002066978A3 (en) Detection of compounds that modulate inflammatory responses
EP1329461A4 (de) Verfahren zur verhinderung von polymeren des humanen serumalbumins
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE270305T1 (de) Peptide des antisekretorischen faktors, welches krankhafte permeabilitätsanderungen reguliert
ATE429927T1 (de) Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
ATE467349T1 (de) Verwendung von wassergräsern als träger für erdbodenlose kultivierung und so gebildeter träger
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60229044D1 (de) Magensaftresistente salze von ketosäuren und aminosäuren und ihre verwendung zur herstellung von medikamenten
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE69431603D1 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
ATE236653T1 (de) Kombination in feste dosiermenge von angiotensin- converting-enzyme-hemmern mit calcium-kanal antagonisten zur behandlung von herz- kreislauferkrankungen
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
DE60326161D1 (de) Modifizierte hydrogele und ihre verwendung
DE60107516D1 (de) Verwendung von Pregabalin zur Asthma Behandlung
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties